176 related articles for article (PubMed ID: 28844154)
41. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice.
Mullane KM; Dubberke ER;
Clin Transplant; 2019 Sep; 33(9):e13564. PubMed ID: 31002420
[TBL] [Abstract][Full Text] [Related]
42. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile.
Early CR; Park JM; Dorsch MP; Pogue KT; Hanigan SM
Transpl Infect Dis; 2016 Oct; 18(5):714-720. PubMed ID: 27501504
[TBL] [Abstract][Full Text] [Related]
43. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
44. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
[TBL] [Abstract][Full Text] [Related]
45. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
[TBL] [Abstract][Full Text] [Related]
46. Recurrent
Song JH; Kim YS
Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
[TBL] [Abstract][Full Text] [Related]
47. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
Aldrete SD; Kraft CS; Magee MJ; Chan A; Hutcherson D; Langston AA; Greenwell BI; Burd EM; Friedman-Moraco R
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943501
[TBL] [Abstract][Full Text] [Related]
48. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
Mizusawa M; Doron S; Gorbach S
Drugs Aging; 2015 Aug; 32(8):639-47. PubMed ID: 26233437
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
Na'amnih W; Adler A; Miller-Roll T; Cohen D; Carmeli Y
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1281-1288. PubMed ID: 29627951
[TBL] [Abstract][Full Text] [Related]
51. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation.
Shah SA; Tsapepas DS; Kubin CJ; Martin ST; Mohan S; Ratner LE; Pereira M; Kapur S; Dadhania D; Walker-McDermott JK
Transpl Infect Dis; 2013 Oct; 15(5):502-9. PubMed ID: 23890202
[TBL] [Abstract][Full Text] [Related]
52. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.
Rodriguez S; Hernandez MB; Tarchini G; Zaleski M; Vatanchi M; Cardona L; Castro-Pavia F; Schneider A
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1856-61. PubMed ID: 24681079
[TBL] [Abstract][Full Text] [Related]
53. Risk factors associated with Clostridium difficile infection in kidney transplant recipients.
Spinner ML; Stephany BR; Cerrato PM; Lam SW; Neuner EA; Patel KS
Transpl Infect Dis; 2018 Aug; 20(4):e12918. PubMed ID: 29797632
[TBL] [Abstract][Full Text] [Related]
54. Preventing downstream Clostridium difficile infections with upstream antibiotic management.
Malkan AD; Scholand SJ
Med Hypotheses; 2012 Jan; 78(1):136-7. PubMed ID: 22079651
[TBL] [Abstract][Full Text] [Related]
55. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
56. Clinical review of Clostridium difficile infection: an update on treatment and prevention.
Daniels LM; Kufel WD
Expert Opin Pharmacother; 2018 Nov; 19(16):1759-1769. PubMed ID: 30220230
[TBL] [Abstract][Full Text] [Related]
57. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
58. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
Gómez S; Chaves F; Orellana MA
Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
[TBL] [Abstract][Full Text] [Related]
59. Clostridium difficile infection among kidney transplant recipients: frequency, clinical presentation, and outcome.
Lionaki S; Panagiotellis K; Moris D; Daikos G; Psyhogiou M; Vernadakis S; Zavos G; Boletis JN
APMIS; 2015 Mar; 123(3):234-9. PubMed ID: 25556694
[TBL] [Abstract][Full Text] [Related]
60. Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
Agha A; Sehgal A; Lim MJ; Weber D; Hou JZ; Farah R; Raptis A; Im A; Dorritie K; Marks S; Agha M; Lim SH
Am J Hematol; 2016 Mar; 91(3):291-4. PubMed ID: 26661725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
